

| B  |   |  |                       |           |  |
|--|---|--|-----------------------|-----------|--|
| Medication   | Dosages & Intervals of Administration   | Route & Final Dilution                                   | Dilution Instructions | Stability | Rate of Infusion & comments  |
| Bovine Lipid Extract Surfactant (BLES)<br><br>27 mg/mL surfactant (phospholipids)<br><br>3 and 5 mL vials<br><br><br><br><br><br><br><br><br>Ref: 27<br>Last update:<br>May 2019 | <b>Used for prophylaxis and treatment of surfactant deficiency/inactivation</b><br><br>Initial: 5 mL/kg/dose (135 mg/kg of surfactant)<br><br>Repeat: 5 mL/kg/dose (135 mg/kg of surfactant) Q6H up to 3 additional doses PRN | Intratracheal administration via endotracheal tube (ETT) |                       |           | <u><b>Comments</b></u><br><br>-Chest x-ray should be done prior to administration to confirm proper ETT position<br><br><b>Monitoring</b><br>Close monitoring of transcutaneous SpO2, CO2, ABG, tidal volumes, peak pressures, and ECG is essential to follow rapid changes in lung compliance and to prevent post-dosing hyperoxia, hypocarbia, and lung trauma<br><br><b>Adverse Effects</b><br>Pulmonary hemorrhage, apnea, ETT obstruction |

| B   |   |  |                       |           |  |
|---|---|--|-----------------------|-----------|--|
| Medication  | Dosages & Intervals of Administration   | Route & Final Dilution                                   | Dilution Instructions | Stability | Rate of Infusion & comments  |
| Bovine Lipid Extract Surfactant (BLES)<br><br>27 mg/mL surfactant (phospholipids)<br><br>3 and 5 mL vials<br><br><br><br><br><br><br><br>Ref: 27<br>Last update: May 2019 | <b>Used for prophylaxis and treatment of surfactant deficiency/inactivation</b><br><br>Initial: 5 mL/kg/dose (135 mg/kg of surfactant)<br><br>Repeat: 5 mL/kg/dose (135 mg/kg of surfactant) Q6H up to 3 additional doses PRN | Intratracheal administration via endotracheal tube (ETT) |                       |           | <b><u>Comments</u></b><br><br>-Chest x-ray should be done prior to administration to confirm proper ETT position<br><br><b><u>Monitoring</u></b><br>Close monitoring of transcutaneous SpO2, CO2, ABG, tidal volumes, peak pressures, and ECG is essential to follow rapid changes in lung compliance and to prevent post-dosing hyperoxia, hypocarbia, and lung trauma<br><br><b><u>Adverse Effects</u></b><br>Pulmonary hemorrhage, apnea, ETT obstruction |